Skip Ribbon Commands
Skip to main content
Skip to main navigation Skip to main content
Sign In

Boehringer Ingelheim Limited named in advertisements for breaches of the ABPI Code of Practice

Boehringer Ingelheim Limited has breached Clause 2 of the ABPI Code of Practice and is the subject of advertisements in the medical, pharmaceutical and nursing press.
Boehringer Ingelheim Limited – Case AUTH/2404/5/11
For issuing a press release to the consumer press which would encourage members of the public to ask their health professional to prescribe Pradaxa for an unlicensed indication, Boehringer Ingelheim was ruled in breach of the following clauses of the Code:
Clause 2          - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry.
Clause 3.2       - Promoting a medicine for an unlicensed indication.
Clause 9.1       - Failing to maintain high standards.
Clause 22.1     - Advertising a prescription only medicine to the public.
Clause 22.2     - Encouraging members of the public to ask their health professional to prescribe a specific prescription only medicine.
The full case report is published in the PMCPA November Code of Practice Review and is also available at
Under provisions in its Constitution and Procedure, the Prescription Medicines Code of Practice Authority (PMCPA) advertises brief details of all cases where companies are ruled in breach of Clause 2 of the Code, are required to issue a corrective statement or are the subject of a public reprimand. 
The advertisements will appear in the BMJ and The Pharmaceutical Journal on 24 December 2011 and The Nursing Standard on 4 January 2012.
*** ends***